Restructuring Expenses

6 Months Ended

Jun. 30, 2022

Restructuring and Related Activities [Abstract]

Restructuring Expenses

Restructuring Expenses

During 2020, the Company announced a company-wide organizational realignment initiative in order to more effectively align its organizational infrastructure and operations with the industry vision of the Autonomous Pharmacy. In the first quarter of 2021, the Company continued its organizational realignment initiative, incurring $2.0 million of employee severance costs and related expenses.

During the first quarter of 2022, the Company initiated certain domestic and international restructuring initiatives, in order to enhance and streamline certain engineering functions for its domestic operations, and to realign its international sales organization to better serve its customers in various international markets. During the first quarter of 2022, the restructuring plans incurred $3.5 million of employee severance costs and related expenses. As of June 30, 2022, the unpaid balance related to these restructuring plans was $1.1 million.

The following table summarizes the total restructuring expense recognized in the Company’s Condensed Consolidated Statements of Operations for the six months ended June 30, 2022 and 2021:

	Six Months Ended June 30,
	2022		2021
	(In thousands)
Cost of product and service revenues	$	156	$	389
Research and development	1,594		105
Selling, general, and administrative	1,777		1,526
Total restructuring expense	$	3,527	$	2,020